Hemophilia clinical trials at UC Davis
1 research study open to eligible people
“This research study will help us learn if the study product (SPK-8011) is safe and effective in reducing bleeding for treating hemophilia A.”
open to eligible males ages 18 years and up
This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.
Sacramento, California and other locations
Our lead scientists for Hemophilia research studies include Adam Giermasz, MD, PhD.